Last reviewed · How we verify

NCT07168941

Evaluation and Refinement of KF-STRIDE Into the Interview!

Not yet recruiting NA Last updated 11 September 2025
What this trial tests

NA trial testing KF-STRIDE in Autism Spectrum Disorder in 30 participants. Not yet recruiting.

Timeline
1 October 2025
Primary endpoint
10 September 2026
1 October 2026

Quick facts

Lead sponsorKessler Foundation
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date1 October 2025
Primary completion10 September 2026
Estimated completion1 October 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kessler Foundation

Who can join

Adults 18 to 65, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examine the acceptability, usability, feasibility, and initial efficacy of KF-STRIDE 3.0, the data from which will serve as a basis for a future fully powered RCT

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of KF-STRIDE

Trials testing the same drug.

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Kessler Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07168941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing